Guido Bellezza
Papers
1
Total Citations
9
H-Index
1
About
Guido Bellezza is a leading urological researcher whose work centers on improving the early detection and risk stratification of prostate cancer. His major contributions focus on the clinical utility of novel biomarkers, particularly the Prostate Health Index (PHI) and its derivative, the percentage of p2PSA to free PSA (%p2PSA). In his highly cited 2015 study, Bellezza demonstrated that these markers significantly outperform traditional PSA testing in predicting aggressive prostate cancer at radical prostatectomy, offering a more precise tool to distinguish clinically significant disease from indolent tumors. This work has been cited 9 times, underscoring its influence in the field of urologic oncology. By refining diagnostic accuracy, Bellezza’s research helps reduce unnecessary biopsies and overtreatment, directly impacting patient management. His findings are particularly valuable for clinicians seeking to identify high-risk cancers early, making him a key figure in the shift toward personalized, biomarker-driven prostate cancer care.
Research Focus
Key Achievements
Top Papers
- 1